HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a $15 price target.
May 25, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Lisata Therapeutics and maintained a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by HC Wainwright & Co. analyst Joseph Pantginis is a positive signal for Lisata Therapeutics. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100